摘要
目的评价甘精胰岛素与地特胰岛素的临床疗效及安全性.方法以2型糖尿病患者为研究对象,在采用口服降糖药治疗后以及三餐前皮下注射诺和锐治疗后空腹及餐后血糖控制不达标,分别加用长效基础胰岛素类似物甘精胰岛素及地特胰岛素,对治疗情况进行回顾性分析,观察各组治疗前后血糖降低水平、糖化血红蛋白、低血糖发生次数.结果口服降糖药或三餐前胰岛素治疗血糖控制不达标加用甘精胰岛素或地特胰岛素后空腹血糖、餐后2 h血糖及糖化血红蛋白有明显的下降,与治疗前相比有统计学意义(P<0.05),但甘精胰岛素组与地特胰岛素组在血糖下降程度、血糖达标所需时间、每日胰岛素用量及低血糖发生方面两组间比较差异无统计学意义(P>0.05).结论甘精胰岛素与地特胰岛素在控制血糖方面同样有效、安全.
Objective To evaluate the clinical efficacy and safety of the insulin detemir. Method We retrospectively analyzed the therapeutic effect of insulin detemir and glargine and insulin glargine for patients with type 2 diabetes whose blood glucose levels could not well-controlled by Oral hypoglycemic agents or Insulin Aspart Injection only. Then we observed the reduce of blood glucose levels, glycated hemoglobin, glycopenia and the incidence of hypoglycemia in each group before and after treatment. Results As compared with those before treatment, fasting blood glucose, the 2-hour postprandial glucose and glycated hemoglobin were all statistically and significantly decreased after the therapy of insulin detemiror insulin glargine （P 〈 0.05 ）. The reduce of blood glucose levels, the time required for the well-controlled blood glucose, insulin dosage and the incidence of hypoglycemia had no statistically differences between the two groups （P 〉 0.05）. Conclusion Insulin glargine has the same therapeutic efficacy and safety with the insulin detemir in blood sugar control.
出处
《昆明医学院学报》
2012年第1期115-117,共3页
Journal of Kunming Medical College
关键词
甘精胰岛素
地特胰岛素
临床疗效
Insulin glargin
Insulin detemir
Clinical efficacy
作者简介
李薇（1973-），女，回族，上海市人，医学学士，主治医师，主要从事内分泌及代谢性疾病临床工作．
